2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6d1,Chronic hand eczema (CHE) is a highly prevalent dermatology-related occupational hazard. This condition, which is a distinct diagnosis from atopic dermatitis (AD), can be quite symptomatic with implications for one's personal and professional life. Many therapeutic interventions exist for CHE, and the current study determined-through network meta-analyses (NMAs)-the relative efficacy of the newer treatments for CHE. Data for eligible studies were identified after systematically reviewing the literature in PubMed and Scopus. Eligible studies were those that had an arm investigating the impact of monotherapy on 12- or 16-week changes in Hand Eczema Severity Index (HECSI) scores. We conducted sensitivity analyses where network meta-regressions were performed to (ecologically) adjust for variation due to age and sex. Base and sensitivity analyses were adjusted for disease severity at baseline. We identified 5 eligible studies-across which there were 10 active comparators. Among the active comparators were two treatments approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CHE, namely, alitretinoin 30 mg once daily (oral) and delgocitinib 20 mg/g twice daily (topical). We estimated pairwise relative effects using the mean difference (i.e., mean reduction) in the respective HECSI scores; furthermore, efficacy was ranked with Surface Under the Cumulative Ranking Curve (SUCRA) values. We attempted to contribute to the existing CHE literature by producing comparative information on its treatments' relative efficacy; moreover, we found no published NMA study on available treatments for CHE before the conduct of our work. Our results can guide clinical decision-making.31:T962,ABSTRACT Introduction Chronic hand eczema (CHE) is a highly prevalent dermatology‐related occupational hazard. This condition, which is a distinct diagnosis from atopic dermatitis (AD), can be quite symptomatic with implications for one's personal and professional life. Many therapeutic interventions exist for CHE, and the current study determined—through network meta‐analyses (NMAs)—the relative efficacy of the newer treatments for CHE. Methods Data for eligible studies were identified after systematically reviewing the literature in PubMed and Scopus. Eligible studies were those that had an arm investigating the impact of monotherapy on 12‐ or 16‐week changes in Hand Eczema Severity Index (HECSI) scores. We conducted sensitivity analyses where network meta‐regressions were performed to (ecologically) adjust for variation due to age and sex. Base and sensitivity analyses were adjusted for disease severity at baseline. Results We identified 5 eligible studies—across which there were 10 active comparators. Among the active comparators were two treatments approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CHE, namely, alitretinoin 30 mg once daily (oral) and delgocitinib 20 mg/g twice daily (topical). We estimated pairwise relative effects using the mean difference (i.e., mean reduction) in the respective HECSI scores; furthermore, efficacy was ranked with Surface Under the Cumulative Ranking Curve (SUCRA) values. Conclusions We attempted to contribute to the existing CHE literature by producing comparative information on its treatments' relative efficacy; moreover, we found no published NMA study on available treatments for CHE before the conduct of our work. Our results can guide clinical decision‐making. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Chronic Hand Eczema: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Chronic Hand Eczema (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Chronic%20Hand%20Eczema\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Chronic Hand Eczema\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Chronic%20Hand%20Eczema\"}]}}"}}]],["$","$L2f",null,{"title":"Chronic Hand Eczema: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Chronic Hand Eczema with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1111/jocd.70552","pmid":"41277505","title":"Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta‐Analysis Study","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-11-24T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70552","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-11-26","doi":"10.1111/jocd.70552","days":"7","issn":"1473-2130","rank":"9","field":"Clinical Medicine","score":"4","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70552","title":"Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta-Analysis Study.","journal":"Journal of cosmetic dermatology","methods":"","results":"We identified 5 eligible studies-across which there were 10 active comparators. Among the active comparators were two treatments approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CHE, namely, alitretinoin 30 mg once daily (oral) and delgocitinib 20 mg/g twice daily (topical). We estimated pairwise relative effects using the mean difference (i.e., mean reduction) in the respective HECSI scores; furthermore, efficacy was ranked with Surface Under the Cumulative Ranking Curve (SUCRA) values.","abstract":"$30","keywords":[],"pubmed_id":"41277505","conclusions":"","publication_date":"2025-11-24T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70552","URL":"https://doi.org/10.1111/jocd.70552","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"12","score":1,"title":["Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta‐Analysis Study"],"author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc. London Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto School of Medicine Toronto Ontario Canada"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London Ontario Canada"}]},{"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}]}],"issued":{"date-parts":[[2025,11,24]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-11-24T10:25:48Z","timestamp":1763979948000,"date-parts":[[2025,11,24]]},"indexed":{"date-time":"2025-11-24T10:29:04Z","timestamp":1763980144965,"date-parts":[[2025,11,24]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000,"date-parts":[[2025,11,24]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70552"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-08-20"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-11-05"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-11-24"}],"deposited":{"date-time":"2025-11-24T10:25:50Z","timestamp":1763979950000,"date-parts":[[2025,11,24]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,11,24]]},"publisher":"Wiley","reference":[{"DOI":"10.1007/s13555‐024‐01312‐y","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.14699","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2025.02.136","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.15179","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365‐2133.2004.06305.x","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257‐024‐00890‐z","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2015.04.005","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cpet.32","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7326/M14‐2385","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Posit team “RStudio: Integrated Development Environment for R ” (2022) http://www.posit.co/.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s13643‐016‐0384‐4","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18295","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365‐2133.2009.09463.x","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1167","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad156","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3310/TWQC0141","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140‐6736(25)00001‐7","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21037","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ClinicalTrials.gov “Safety and Efficacy of ARQ‐252 Cream in Subjects With Chronic Hand Eczema ” (2025) https://clinicaltrials.gov/study/NCT04378569#study‐overview.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Eczema Association “Breaking News: FDA Approves the First Treatment for Moderate‐to‐Severe Chronic Hand Eczema | National Eczema Association ” (2025) https://nationaleczema.org/blog/breaking‐news‐fda‐approves‐the‐first‐treatment‐for‐moderate‐to‐severe‐chronic‐hand‐eczema/.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Medscape “Delgocitinib Approved in Europe for Chronic Hand Eczema ” (2024) https://www.medscape.com/viewarticle/european‐commission‐approves‐delgocitinib‐chronic‐hand‐2024a1000ht7.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/14651858.CD004055.pub2","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.14438","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18502/ijph.v49i7.3588","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/ACTADV.V105.42198","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2025.04.062","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70552"],"article-number":"e70552","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,12]]},"reference-count":27,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,24]]},"references-count":27,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70552","is_oa":true,"title":"Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta‐Analysis Study","updated":"2025-11-29T00:16:09+00:00","published_date":"2025-11-24","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70552","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70552","url_for_landing_page":"https://doi.org/10.1111/jocd.70552"}}},"created_at":"2025-11-29T07:06:31.192Z","updated_at":"2025-12-02T07:03:10.886Z","tags":[{"paper_doi":"10.1111/jocd.70552","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"condition","value":"Chronic Hand Eczema","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"generic","value":"alitretinoin","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"generic","value":"delgocitinib","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"study_design","value":"Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"warning","value":"No numeric effect sizes or SUCRA rankings are reported in the abstract, so the superior treatment cannot be identified here.","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"warning","value":"The designs of included studies (e.g., RCT vs non‑RCT) are not specified, so evidence level cannot be assigned.","value_numeric":null},{"paper_doi":"10.1111/jocd.70552","tag_type":"warning","value":"Total participant sample size is not provided.","value_numeric":null}],"summaries":{"what_studied":"A network meta-analysis compared monotherapy treatments for chronic hand eczema using 12– or 16–week changes in Hand Eczema Severity Index (HECSI) scores. It synthesized 5 studies with 10 active comparators, including alitretinoin 30 mg once daily (oral) and delgocitinib 20 mg/g twice daily (topical), with analyses adjusted for baseline severity and sensitivity meta‑regressions for age and sex.","limitations":"Only five studies informed the network, and adjustments for age and sex were ecological rather than patient‑level. The abstract does not report effect sizes or SUCRA rankings."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Chronic Hand Eczema"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Chronic Hand Eczema"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Chronic Hand Eczema"}}}]]

Papers